Medicines in exceptional circumstances for solid tumours: focusing on evidence, effectiveness, and toxicity profiles Alberto Artiles-Medina; Marina Sáchez-Cuervo; Victoria Gómez-Dos Santos; Emilio J. Sanz-Álvarez; Ana Álvarez-Díaz; Francisco Javier Burgos-Revilla;

Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain José Ramón González-Porras; Francisco Javier Parrondo García; Eduardo Anguita;